Medicare drug coverage

Restasis: 2027 Medicare Part D coverage

3,104 of 5,495 Part D plans (56%) list Restasis on their 2027 formulary, the plan's list of covered drugs (down 4 points from 2026). 69% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).

License: a US government work, in the public domain (Public Domain Mark 1.0).

Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.

For pharmacies and agencies: check a whole drug list against 2027 formularies.

Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.

2027 compared with 2026

Restasis is number 38 by total Medicare Part D spending in 2024 ($1.3 billion). Plans that list it most often put it on tier 3 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 3 RxNorm products for this name.

Restasis Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it3,319 (60%)3,104 (56%)-4 points
Prior authorization (of plans that list it)0 (0%)0 (0%)no change
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)2,474 (75%)2,135 (69%)-6 points
Any of the three (of plans that list it)2,474 (75%)2,135 (69%)-6 points
Not listed or restricted (of all plans)4,673 (85%)4,526 (82%)-3 points

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Every 2027 stand-alone drug plan

Each stand-alone Part D plan (PDP) with Restasis's 2027 tier and limits. CMS files a PDP once per region, so one plan name can have several plan IDs; the row shows the tier and limits most of them use. Medicare Advantage drug plans are local: pick a state for its plan-by-plan table.

Restasis on every 2027 stand-alone Part D plan
Plan (PDP)Plan IDs2027 tier2027 limits
AARP Medicare Rx Preferred from UHC (PDP)39Tier 3QL
AARP Medicare Rx Saver from UHC (PDP)34Not listedNot listed
Blue Medicare Rx Enhanced (PDP)1Tier 3QL
Blue Medicare Rx Standard (PDP)1Tier 3QL
Blue MedicareRx Essentials (PDP)1Not listedNot listed
Blue MedicareRx Plus (PDP)1Not listedNot listed
Blue MedicareRx Premier (PDP)1Tier 3None
Blue MedicareRx Value (PDP)1Not listedNot listed
Blue MedicareRx Value Plus (PDP)1Tier 3None
Blue Shield Rx Enhanced (PDP)1Tier 3QL
Blue Shield Rx Plus (PDP)1Tier 3QL
BlueMedicare Complete Rx (PDP)1Not listedNot listed
BlueMedicare Premier Rx (PDP)2Tier 3None (1 of 2 IDs)
BlueMedicare Value Rx (PDP)1Tier 3None
BlueRx Enhanced Plus (PDP)1Not listedNot listed
BlueRx Essential (PDP)1Not listedNot listed
HealthSpring Assurance Rx (PDP)35Not listedNot listed
HealthSpring Extra Rx (PDP)2Not listedNot listed
HealthSpring Extra RX (PDP)3Not listedNot listed
Horizon Medicare Blue Rx Enhanced (PDP)1Not listedNot listed
Horizon Medicare Blue Rx Standard (PDP)1Not listedNot listed
Humana Basic Rx Plan (PDP)34Not listedNot listed
Humana Premier Rx Plan (PDP)34Not listedNot listed
Humana Value Rx Plan (PDP)34Not listedNot listed
MedicareBlue Rx Standard (PDP)1Not listedNot listed
Prescription Blue Premium (PDP)1Tier 3QL
Prescription Blue Select (PDP)1Tier 3QL
SilverScript Choice (PDP)20Tier 3QL
Wellcare Classic (PDP)34Not listedNot listed
Wellcare Value Script (PDP)34Not listedNot listed

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Formulary tier

Restasis formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 178 (2%)34 (1%)
Tier 23 (<1%)0 (0%)
Tier 33,238 (98%)3,070 (99%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan IDs are in both files. 81 of them (2%) added prior authorization, step therapy, or a quantity limit for Restasis, and 275 stopped listing it.

Restasis: plans in both 2026 and 2027
Plan by planPlans
Same plan ID in both years4,380
Listed it in 2026, not in 2027275 (6%)
Listed it in 2027, not in 202621 (<1%)
Moved it to a higher tier14 (<1%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit81 (2%)
Added at least one of the three81 (2%)
Removed at least one of the three0 (0%)
Plan IDs new in 20271,115
2026 plan IDs not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Restasis off the formulary or list it with prior authorization, step therapy, or a quantity limit. 7 states tie for the highest share, 100%; Massachusetts ranks last at 41%. States at the same share are marked Tied and share a rank.

States from most to least restrictive for Restasis, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
Tied 1Alaska9100%0%no change
Tied 1Montana27100%0%no change
Tied 1North Dakota26100%0%+15 points
Tied 1Nevada100100%0%+6 points
Tied 1South Dakota30100%0%+20 points
Tied 1West Virginia70100%0%no change
Tied 1Wyoming13100%0%no change
8Minnesota6398%0%+7 points
9California39797%0%+5 points
Tied 10District of Columbia2195%0%-1 point
Tied 10Wisconsin9795%0%+14 points
12Idaho4593%0%+7 points
13New Jersey7492%0%no change
Tied 14Kentucky12389%0%-2 points
Tied 14Georgia15189%0%-3 points
Tied 14Pennsylvania32489%0%-2 points
Tied 14South Carolina9189%0%+8 points
Tied 18Delaware4388%0%-5 points
Tied 18Virginia14588%0%-4 points
20Kansas8487%0%-5 points
Tied 21Rhode Island2986%0%-1 point
Tied 21Vermont1486%0%+1 point
Tied 23Texas41285%0%-4 points
Tied 23Michigan18385%0%-6 points
Tied 23Oklahoma8185%0%-5 points
Tied 23Utah5385%0%-3 points
Tied 23Mississippi10585%0%+1 point
Tied 23Maine5285%0%-2 points
Tied 29Iowa6483%0%+11 points
Tied 29Arkansas8683%0%no change
Tied 31New Mexico6882%0%-5 points
Tied 31Missouri17182%0%-6 points
Tied 31Louisiana12682%0%-10 points
Tied 34Nebraska5180%0%+2 points
Tied 34Colorado10680%0%-8 points
Tied 34Florida54980%0%-1 point
Tied 34North Carolina17780%0%-5 points
38Washington11478%0%-16 points
Tied 39Ohio17377%0%-3 points
Tied 39Indiana14077%0%-3 points
Tied 39New York21577%0%+2 points
Tied 42New Hampshire2576%0%-24 points
Tied 42Illinois13376%0%-4 points
Tied 44Arizona14874%0%-5 points
Tied 44Connecticut5474%0%-5 points
Tied 46Tennessee15771%0%-8 points
Tied 46Oregon9271%0%-22 points
Tied 48Maryland4965%0%-18 points
Tied 48Alabama11565%0%-10 points
50Hawaii5052%0%-4 points
51Massachusetts9241%0%-1 point

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Restasis off or restrict it.

Restasis coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
HealthPartners, Inc.7100%100%100%no change0
Johns Hopkins Healthcare LLC7100%0%0%no change0
Network Health, Inc.70%none list it100%no change0
Singh Holdings LLC7100%100%100%no change0
Astiva Health Holdings Incorporated80%none list it100%no change0
Healthfirst, Inc.8100%0%0%no change0
Longevity Health Founders, LLC80%none list it100%no change0
MVP Health Care, Inc.8100%0%0%no change0
Martin's Point Health Care, Inc.8100%0%0%no change0
Triton Health Systems, L.L.C.8100%0%0%no change0
DOCTORS HEALTHCARE PLANS, INC.90%none list it100%no change0
EmblemHealth, Inc.90%none list it100%no change0
Perennial Consortium, LLC90%none list it100%no change0
West Virginia United Health System, Inc.90%none list it100%no change0
Aware Integrated, Inc.100%none list it100%no change0
Gemstone Holdings, Inc.10100%100%100%no change0
Intermountain Health Care, Inc.100%none list it100%no change0
Thomas Jefferson University100%none list it100%no change0
ATRIO Health Plans110%none list it100%no change0
Curana Health Holdings, LLC120%none list it100%no change0
Fallon Community Health Plan, Inc.12100%0%0%no change0
Louisiana Health Service & Indemnity Company120%none list it100%no change0
Cambia Health Solutions, Inc.130%none list it100%no change0
Clover Health Holdings, Inc.13100%100%100%+100 points13
Henry Ford Health System130%none list it100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Other Cyclosporine products

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.